(Photo Courtesy: www.heartregistry.org.au)
The collaboration provides up to $200 million in equity investments, milestone payments, and R&D services through 2018.
MyoKardia is a privately-held US-company, leading the development of precision therapies for genetic heart disease.
The collaboration builds upon MyoKardia's pioneering science, which hopes to correct the disruptive effects that disease mutations have on heart muscle contraction.
The collaboration, representing one of the largest research and development commitments to genetic forms of cardiomyopathy, encompasses three MyoKardia programs.
Two of these programs are focused on hypertrophic cardiomyopathy (HCM) and the other is focused on dilated cardiomyopathy (DCM).